The Court of Appeal in Paris has ruled that Sanofi must pay 150.7 million euros to CNAM as compensation for anti-competitive practices related to the drug Plavix.

The court's decision is based on a ruling from 2013, when Sanofi was fined 40.6 million euros for actions against generic drug manufacturers. The court found that the impact of these practices persisted until 2021, although the anti-competitive behavior lasted only five months. CNAM will receive 126.2 million euros for reimbursements and fees, plus 24.5 million euros in damages. Sanofi is reviewing the ruling and considers the possibility of an appeal to the Supreme Court.